News

   

Poolbeg Pharma plc – POLB 001 cancer immunotherapy-induced CRS patent granted in Canada

Further strengthening of Poolbeg's global intellectual property…
Vianautis

Poolbeg Pharma plc – Results for the year ended 31 December 2025

28 April 2026 - Poolbeg Pharma (AIM: POLB, 'Poolbeg' or the…

Oncoinvent ASA: Annual Report for 2025

Oslo, Norway, 22 April 2026 - Oncoinvent ASA (ONCIN), a biotech…

Hansa Biopharma Report First Quarter 2026 Financial Results

· PDUFA target date set for December 19 by the FDA ·…
xeltis
xeltis

Xeltis receives CE mark for aXess™, its aXess hemodialysis conduit ™, as it moves to commercialization

CE mark awarded for aXess™ at record speed, underpinned…

New Nordic white paper reveals systemic barriers preventing women from reaching leadership roles

Report outlines 17 targeted actions to address structural barriers…

We’d love to hear from you.

For more information about Optimum Strategic Communications, please get in touch.

© Optimum Strategic Communications.